Kalaris Therapeutics (KLRS) vs Instil Bio (TIL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Instil Bio (TIL) has outperformed Kalaris Therapeutics (KLRS) over the past year, losing 60.2% versus a loss of 81.7%. Over five years, TIL leads with a -98.7% price change compared with -99.7% for KLRS. Instil Bio is the larger company by market cap ($35.5 million vs $30.5 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | KLRS | TIL |
|---|---|---|
| Share price | $1.28 | $5.23 |
| Market cap | $30.47M | $35.47M |
| 1-day change | -5.19% | -5.77% |
| YTD return | -84.83% | -52.45% |
| 1-year return | -81.74% | -60.20% |
| 5-year return | -99.70% | -98.72% |
| EPS (TTM) | $-1.84 | $-3.09 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $10.77M |
| Revenue growth (YoY) | — | +152.38% |
| Net income (latest FY) | $-43.44M | $-71.37M |
| Operating margin | — | -745.39% |
| Net margin | — | -662.75% |
| 52-week high | $11.88 | $12.92 |
| 52-week low | $1.25 | $5.14 |
| Distance from 52-week high | -89.23% | -59.51% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +1361.72% | +33.84% |
| Average volume | 77.37K | 42.02K |
| Shares outstanding | 23.80M | 6.78M |
| Employees | 20 | 17 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- TIL has outperformed KLRS by 21.5 percentage points over the past year.
About Kalaris Therapeutics
KLRS stock →Kalaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for prevalent retinal diseases. It develops TH103, a clinical-stage anti-vascular endothelial growth factor (VEGF) drug for the treatment of neovascular age-related macular degeneration (nAMD), which is in Phase 1b/2, as well as for the treatment of other exudative and neovascular retinal diseases.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 20 employees
About Instil Bio
TIL stock →Instil Bio, Inc., a biopharmaceutical company, focuses on identifying and advancing therapeutic opportunities. It seeks to in-license or acquire and develop additional novel therapeutic candidates in diseases with significant unmet medical need.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 17 employees
KLRS vs TIL FAQ
Which is bigger, Kalaris Therapeutics or Instil Bio?
Instil Bio (TIL) is larger, with a market capitalization of $35.47M compared with $30.47M for Kalaris Therapeutics (KLRS).
Which stock has performed better over the past year, KLRS or TIL?
TIL returned -60.20% over the past 12 months, compared with -81.74% for KLRS (price return, excluding dividends). Past performance does not predict future results.
Are Kalaris Therapeutics and Instil Bio in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.